Investor Relations

Sunshine Heart is a global medical technology company, committed to the commercialization of C-Pulse®, an implantable, non-blood contacting, heart assist therapy for the treatment of people with class III and ambulatory class IV heart failure. Sunshine Heart is listed on the NASDAQ Capital Market.

Press Releases

Posted on Jan 19, 2016
EDEN PRAIRIE, Minn., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH), today announced that on January 14, 2016, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award to Eric Lovett, Ph.D. under Sunshi...

Read More

Posted on Jan 5, 2016
EDEN PRAIRIE, Minn., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Eric Lovett Ph.D., to the position of Vice President, Clinical Affairs. In this capacity, Dr. Lovett will manage the Company's U.S. pivotal study (COUNTER HF™) for its ...

Read More

Posted on Dec 9, 2015
EDEN PRAIRIE, Minn., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today it has amended its debt agreement with Silicon Valley Bank to modify the requirement that the Company raise $20.0 million by March 31, 2016. "It is a pleasure to continue to work with Sili...

Read More

Events & Presentations